Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: A meta-analysis

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 5, 2014, Pages 725-733

  Treglia, Giorgio ^a   Ceriani, Luca ^a   Sadeghi, Ramin ^b   Giovacchini, Giampiero ^c   Giovanella, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TRIEMLI HOSPITAL   (Switzerland)

Author keywords

choline; positron emission tomography; prostate cancer; prostate specific antigen (PSA); PSA kinetics

Indexed keywords

CHOLINE; PROSTATE SPECIFIC ANTIGEN; CARBON; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; ISOTOPE LABELING; META ANALYSIS (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DOUBLING TIME; PROSTATE SPECIFIC ANTIGEN VELOCITY; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; REFERENCE VALUE; SYSTEMATIC REVIEW; BLOOD; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FACTUAL DATABASE; KINETICS; MALE; META ANALYSIS; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SCINTISCANNING;

CARBON RADIOISOTOPES; CHOLINE; DATABASES, FACTUAL; FLUORINE RADIOISOTOPES; HUMANS; KINETICS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84898979366     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0675     Document Type: Article

References (34)

1. Marta GN, Hanna SA, Fernandes da Silva JL, Carvalho Hde A. Screening for prostate cancer: an updated review. Expert Rev Anticancer Ther 2013;13:101-8.
2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al., European Association of Urology. EAU guidelines on prostate cancer: part 1. Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
3. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer: part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23. (Pubitemid 36132976)
5. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D′Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540-5. (Pubitemid 46054056)
6. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
7. O′Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27:3591-7
8. Schiavina R, Brunocilla E, Borghesi M, Vagnoni V, Castellucci P, Nanni C, et al. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: How to differentiate local from systemic disease? The urologist point of view. Rev Esp Med Nucl Imagen Mol 2013;32:310-3.
9. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003;170:2274-8. (Pubitemid 37413974)
10. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006;106:1047-53.
11. Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 2013;38:305-14.
12. Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012;26:451-61.
13. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413-39. (Pubitemid 30016999)
14. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-14. (Pubitemid 34016349)
15. Evangelista L, Cervino AR, Burei M, Gregianin M, Saladini G, Marzola MC, et al. Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis. Clin Transl Imaging 2013;1;99-109.
16. Giovacchini G, Breeuwsma AJ. Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline. Q J Nucl Med Mol Imaging 2012;56:354-66.
17. 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 2013;54:833-40.
18. Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, et al. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging 2013;40:149-55.
19. 11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol 2013;189:105-10.
20. 11C-choline pet imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level < 0.5 ng/mL. Clin Nucl Med 2013;38:e342-5.
21. 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med 2013;38:e26-32.
22. 11C-choline positron emission tomography in recurrent prostate cancer. World J Urol 2013;31:319-23.
23. 11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy. Q J Nucl Med Mol Imaging 2012;56:440-6.
24. 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med 2012;37: 325-31.
25. 18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012;39:271-82.
26. 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012;39:589-96.
27. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011;97:49-55.
28. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase < 1.5 ng/ml? Eur J Nucl Med Mol Imaging 2011;38:55-63.
29. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of [(11)C] choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:1106-16.
30. 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394-400.
31. Sadeghi R, Treglia G. Meta-analyses and systematic reviews on PET and PET/CT in oncology: the state of the art. Clin Transl Imaging 2013;1:73-5.
32. 11C-Choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 2013;40:S36-40.
33. Ratib O. PET/MRI: a new era in multimodality molecular imaging. Clin Transl Imaging 2013;1:5-10.
34. Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M. Whole-body PET/MRI in oncology: current status and clinical applications. Clin Transl Imaging 2013;1:31-44.